Results 251 to 260 of about 390,635 (308)
Some of the next articles are maybe not open access.
Modeling RASopathies with Genetically Modified Mouse Models.
Methods in molecular biology, 2017The RAS/MAPK signaling pathway plays key roles in development, cell survival and proliferation, as well as in cancer pathogenesis. Molecular genetic studies have identified a group of developmental syndromes, the RASopathies, caused by germ line mutations in this pathway.
Isabel Hernández-Porras, C. Guerra
semanticscholar +3 more sources
Genetically Modified Mouse Models of Adamantinomatous Craniopharyngioma
, 2017Over the last few years, there have been significant advances in the understanding of the pathogenesis of human adamantinomatous craniopharyngioma. Global and gene-specific expression studies of human biopsies have helped to delineate the network of pathways involved in the initiation and establishment of these tumours.
C. Andoniadou, J. Martínez-Barbera
semanticscholar +2 more sources
PROBABILITY LEARNING IN GENETICALLY MODIFIED MOUSE LINES
Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science), 2018A. Tkachenko +3 more
semanticscholar +2 more sources
Regression of atherosclerosis: lessons learned from genetically modified mouse models
Current Opinion in Lipidology, 2018Purpose of review Regression, or reversal, of atherosclerosis has become an important clinical objective. The development of consistent models of murine atherosclerosis regression has accelerated this field of research. The purpose of this review is to highlight recent mouse studies that reveal molecular mechanisms as well as ...
A. Burke, M. Huff
semanticscholar +3 more sources
Genetically modified mouse models for pharmacogenomic research
Nature Reviews Genetics, 2004It is now evident that differences in the DNA sequence of genes involved with drug action can lead to interindividual differences in effectiveness and adverse reactions to therapeutic drugs. Pharmacogenomics raises the possibility that drug discovery and patient management could move from a 'one drug fits all' approach to one in which therapy is ...
S. Liggett
semanticscholar +3 more sources
Genetically modified mouse models for premature ovarian failure (POF)
Molecular and Cellular Endocrinology, 2010Premature ovarian failure (POF) is a complex disorder that affects approximately 1% of women. POF is characterized by the depletion of functional ovarian follicles before the age of 40 years, and clinically, patients may present with primary amenorrhea or secondary amenorrhea.
K. Jagarlamudi +3 more
semanticscholar +3 more sources
Genetically modified mouse models in cancer studies
Clinical and Translational Oncology, 2008Genetically modified animals represent a resource of immense potential for cancer research. Classically, genetic modifications in mice were obtained through selected breeding experiments or treatments with powerful carcinogens capable of inducing random mutagenesis.
Javier Santos +4 more
semanticscholar +3 more sources
Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Clinical Cancer Research, 2012Abstract The ability to grow pluripotent mouse embryonic stem cells in culture, and to introduce precise genetic modifications into those cells through gene targeting, has greatly facilitated the generation of mouse models of human disease. This technology is playing a particularly important role in cancer research.
R. Kucherlapati
semanticscholar +3 more sources
In vivo Studies of the Genetically Modified Mouse Kidney
Nephron Physiology, 2003Gene-targeted mice provide a powerful approach to study the physiological and pathophysiological role of a given protein in kidney function and can give insights on the functional importance of these proteins under in vivo conditions as well as on the potential compensating mechanisms in their absence.
V. Vallon
semanticscholar +3 more sources
Noonan syndrome: lessons learned from genetically modified mouse models
Expert Review of Endocrinology & Metabolism, 2017Noonan syndrome is a RASopathy that results from activating mutations in different members of the RAS/MAPK signaling pathway. At least eleven members of this pathway have been found mutated, PTPN11 being the most frequently mutated gene affecting about 50% of the patients, followed by SOS1 (10%), RAF1 (10%) and KRAS (5%). Recently, even more infrequent
Alberto J. Schuhmacher +3 more
openaire +2 more sources